Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by University Health Network, Toronto
Sponsor:
Information provided by (Responsible Party):
Dheeraj Rajan, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01200914
First received: September 10, 2010
Last updated: January 17, 2014
Last verified: January 2014

September 10, 2010
January 17, 2014
January 2011
January 2015   (final data collection date for primary outcome measure)
Target lesion primary patency at 3, 6, and 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01200914 on ClinicalTrials.gov Archive Site
Target lesion secondary patency at 3, 6, and 12 months, access circuit primary and secondary patency at 3, 6, and 12 months, anatomic, clinical, and procedural success. Adverse events through 1 month [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins
Placement of Covered Stents to Treat Hemodialysis Access Stenosis in the Cephalic Arch and Central Veins

Balloon angioplasty is used to open up a narrowing that forms in hemodialysis fistula. Two areas of particular problems are the terminal portion of the cephalic vein near the shoulder and the central veins in the chest. Although angioplasty is standard of care the treated narrowed segments of vein mostly renarrow within 3 months requiring retreatment to keep your dialysis access functional. Recently there has been introduction of a new technology called a covered stent graft. Initial studies suggest that placing this device across the area of narrowing leads to dialysis access staying open longer and needing less angioplasty treatments.

This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.

This is a randomized, prospective, unblinded study with 1:1 randomization. Both groups will undergo PTA of stenotic lesion and patients will be randomized such that 50% will receive a covered stent in addition to the PTA. Patients will be followed at 3, 6, and 12 months post-procedure. Follow-up will be conducted with either angiographic and/or transonic measurements.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Renal Failure
  • Device: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
    The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
    Other Name: Covered stent
  • Procedure: PTA alone without use of the GORE VIABAHN
    Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
  • Active Comparator: 'PTA without use of the GORE VIABAHN'
    Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
    Intervention: Procedure: PTA alone without use of the GORE VIABAHN
  • Experimental: PTA with covered stent
    Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
    Intervention: Device: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
140
January 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study.
  • The patient is ≥ 18 years of age.
  • The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
  • The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
  • The patient or his/her legal guardian is willing to provide informed consent.
  • The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.

Exclusion Criteria:

  • The patient has a known or suspected systemic infection.
  • The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
  • The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
  • The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
  • The patient has known sensitivity to heparin.
  • The patient is scheduled for a live donor kidney transplant.
  • The patient is enrolled in another investigational study or another access maintenance trial
  • The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements.
  • Life expectancy is ≤ 24 months.
  • The patient has an untreatable allergy to radiographic contrast material.
  • The patient is pregnant.
  • In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
  • The patient's access is planned to be abandoned within 1 year.
  • The patient has indwelling catheters (dialysis, pacemakers, ports).
  • The patient has a central vein stent that would lead to jailing of the internal jugular vein.
  • The patient experiences angioplasty-induced venous rupture.
  • The patient has a flow limiting dissection after angioplasty.
  • The patient's hemodialysis access is thrombosed.
Both
18 Years and older
No
Contact: Dheeraj Rajan, M.D. 416-340-4911/603-6276 Dheeraj.Rajan@uhn.on.ca
Canada
 
NCT01200914
GORE-001
No
Dheeraj Rajan, University Health Network, Toronto
University Health Network, Toronto
Not Provided
Principal Investigator: Dheeraj Rajan, M.D. Physician
University Health Network, Toronto
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP